The Lancet Respiratory Medicine - Phase 3 Study of Lenzilumab

The Lancet published a study confirming positive Phase 3 results of Lenzilumab for the treatment of hospitalized patients with COVID-19.

The study, funded by Humanigen, leveraged insights from the BioSymetrics Platform to inform clinical strategy and study design.

View the full study here.